Shire plc and ArmaGen have entered a worldwide licensing and collaboration agreement for AGT-182, an investigational enzyme replacement therapy (ERT) for the potential treatment of the central nervous system (CNS) and somatic manifestations in Hunter syndrome (MPS II).   Shire will obtain worldwide commercialization rights for AGT-182 for approximately $225 million, including an initial upfront payment of $15 million in cash and equity, an additional equity investment, R&D funding, developme...